Results 161 to 170 of about 592,770 (271)

Serotonin engages divergent 5‐HT receptor pathways for cell type‐resolved modulation of prefrontal layer 5 microcircuits

British Journal of Pharmacology, Volume 183, Issue 19, Page 5832-5853, October 2026.
Serotonin differentially modulates layer 5 mPFC microcircuits through cell type‐specific pre‐ and postsynaptic receptor pathways. Presynaptic 5‐HT1BRs suppress glutamate and GABA release, whereas presynaptic and postsynaptic 5‐HT3ARs enhance fast‐spiking interneuron activity, whilst distinct pyramidal neuron subtypes exhibit divergent 5‐HT1AR‐ and 5 ...
Ramya Rama, Guanxiao Qi, Gabriele Radnikow, Danqing Yang, Dirk Feldmeyer   +4 more
wiley   +1 more source

Muscarinic Receptor PET in Neurodegeneration: Promise, Pitfalls, and Translational Priorities. [PDF]

Med Sci (Basel)
Filippi L, Danieli R.
europepmc   +1 more source

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, Volume 183, Issue 19, Page 5701-5731, October 2026.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source

Role of Muscarinic Receptor Signaling Processes in Specific Aspects of Morphine-Induced Respiratory Depression in Rats. [PDF]

Pharmaceuticals (Basel)
Getsy PM, May WJ, Baby SM, Coffee GA, Qiu Y, Cheng F, Bates JN, Lewis SJ.   +7 more
europepmc   +1 more source

Comprehensive in vitro profiling of traditional and emerging stimulants at monoamine transporters and the 5‐HT2A receptor

British Journal of Pharmacology, Volume 183, Issue 19, Page 5871-5894, October 2026.
A pharmacological profiling of 58 synthetic stimulants of various classes at dopamine, norepinephrine, and serotonin transporters and the 5‐HT2A receptor, most showing distinct class‐dependent profiles, with some indicating a high abuse potential. Background and Purpose New psychoactive substances (NPSs) often emerge on the illicit drug market with ...
Darta Stalberga, Robert Kronstrand, Bianca Schranz, Nick van Zijl, Sebastian Karlman, Soma Aref, Tobias Rautio, Svante Vikingsson, Mattias Persson, Henrik Green   +9 more
wiley   +1 more source

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies

European Journal of Clinical Investigation, Volume 56, Issue 10, October 2026.
COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Sasha Raman, Sreya Rahman, Francesca Polverino, Muhammad Adrish   +3 more
wiley   +1 more source

Toward a Pluralistic Model for the Schizophrenia Spectrum-Dopamine and Beyond. [PDF]

JAMA Psychiatry
Keshavan MS, Nasrallah HA, Abi-Dargham A, Grace AA, Javitt DC, Lewis DA, Marder SR, Meyer JM, Murray RM, Öngür D, Stahl SM, Tandon R.   +11 more
europepmc   +1 more source

The mechanism of action and clinical efficacy of xanomeline-trospium in schizophrenia: A comprehensive review. [PDF]

Ther Adv Psychopharmacol
Ji F, Ma L, Shen X, Liang X, Cui W, Zhou Y, Wang XE, Liu H.   +7 more
europepmc   +1 more source

Xanomeline-Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia. [PDF]

Int J Mol Sci
Mansour GK, Hajjar AW, Hajjar AH, Alissa A, Sukkarieh HH.   +4 more
europepmc   +1 more source